Cancer biology and genomics: Translating discoveries, transforming pathology

Journal of Pathology

Volumn 223, Issue 2, 2011, Pages 99-101

  Ladanyi, Marc ^a   Hogendoorn, Pancras C W ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

biology; cancer; genomics; targeted therapies; translational medicine

Indexed keywords

CLINICAL ASSESSMENT; GENE TARGETING; GENOMICS; HUMAN; MULTIPLE CANCER; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

GENOMICS; HUMANS; NEOPLASMS; TRANSLATIONAL RESEARCH;

EID: 78649992228     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2812     Document Type: Review

References (39)

1. Hall PA, Lane DP,. Preface to molecular and cellular themes in cancer research. J Pathol 1999; 187: 2-3.
2. Hall PA, Lowe SW,. Molecular and cellular themes in cancer research: II. J Pathol 2005; 205: 121-122.
3. Druker BJ, Talpaz M, Resta DJ, et al., Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
4. Verweij J, Casali PG, Zalcberg J, et al., Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-1134.
5. Blanke CD, Rankin C, Demetri GD, et al., Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626-632.
6. Davies H, Bignell GR, Cox C, et al., Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
7. Pao W, Miller V, Zakowski MF, et al., EGF receptor gene mutations are common in lung cancers from 'never smokers' and correlate with sensitivity of tumors to gefitinib (Iressa) and erlotinib (Tarceva). Proc Natl Acad Sci USA 2004; 101: 13306-13311.
8. Lynch TJ, Bell DW, Sordella R, et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
9. Paez JG, Janne PA, Lee JC, et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
10. Mok TS, Wu YL, Thongprasert S, et al., Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
11. Koivunen JP, Mermel C, Zejnullahu K, et al., EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008; 14: 4275-4283.
12. Flaherty KT, Puzanov I, Kim KB, et al., Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819.
13. Pao W, Iafrate AJ, Su Z,. Genetically-informed lung cancer medicine. J Pathol 2011; 223: 231-241.
14. Ko JM, Fisher DE,. A new era: melanoma genetics and therapeutics. J Pathol 2011; 223: 242-251.
15. Vakiani E, Solit DB,. KRAS and BRAF: Drug targets and predictive biomarkers. J Pathol 2011; 223: 220-230.
16. Antonescu CR,. The GIST paradigm: lessons for other kinase-driven cancers. J Pathol 2011; 223: 252-262.
17. Taylor BS, Ladanyi M,. Clinical cancer genomics: how soon is now? J Pathol 2011; 223: 319-327.
18. Farazi TA, Spitzer JI, Morozov P, et al., miRNAs in human cancer. J Pathol 2011; 223: 102-115.
19. Prives C, Hall PA,. The p53 pathway. J Pathol 1999; 187: 112-126.
20. Lozano G, Zambetti GP,. What have animal models taught us about the p53 pathway? J Pathol 2005; 205: 206-220.
21. Jackson JG, Post SM, Lozano G,. Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. J Pathol 2011; 223: 127-137.
22. Goh AM, Coffill CR, Lane DP,. The role of mutant p53 in human cancer. J Pathol 2011; 223: 116-126.
23. Macleod KF, Jacks T,. Insights into cancer from transgenic mouse models. J Pathol 1999; 187: 43-60.
24. Maddison K, Clarke AR,. New approaches for modelling cancer mechanisms in the mouse. J Pathol 2005; 205: 181-193.
25. Lyons SK,. Advances in imaging mouse tumour models in vivo. J Pathol 2005; 205: 194-205.
26. Berger AH, Pandolfi PP,. Haploinsufficiency: a driving force in cancer. J Pathol 2011; 223: 138-147.
27. Bennett WP, Hussain SP, Vahakangas KH, et al., Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol 1999; 187: 8-18.
28. Simpson PT, Reis-Filho JS, Gale T, et al., Molecular evolution of breast cancer. J Pathol 2005; 205: 248-254.
29. Isaacson PG, Du MQ,. Gastrointestinal lymphoma: where morphology meets molecular biology. J Pathol 2005; 205: 255-274.
30. Aster JC, Blacklow SC, Pear WS,. Notch signalling in T cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol 2011; 223: 263-274.
31. De Jong D, Balagué Ponz O,. The molecular background of aggressive B-cell lymphomas as a basis for targeted therapy. J Pathol 2011; 223: 275-283.
32. Kern SE, Shi C, Hruban RH,. The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. J Pathol 2011; 223: 296-307.
33. Flavin R, Zadra G, Loda M,. Metabolic alterations and targeted therapies in prostate cancer. J Pathol 2011; 223: 284-295.
34. Bombonati A, Sgroi DC,. The molecular pathology of breast cancer progression. J Pathol 2011; 223: 308-318.
35. Nguyen DX,. Tracing the origins of metastasis. J Pathol 2011; 223: 196-205.
36. Allen M, Jones JL,. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 2011; 223: 163-177.
37. Gregory CD, Pound CD,. Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues. J Pathol 2011; 223: 178-195.
38. ten Dijke P,. The dynamic roles of TGF-β in cancer. J Pathol 2011; 223: 206-219.
39. Alison MR, Lim SML, Nicholson LJ,. Cancer stem cells: problems for therapy? J Pathol 2011; 223: 148-162.